Cargando…

Interaction of GC376, a SARS-COV-2 M(PRO) inhibitor, with model lipid membranes

Partitioning and effect of antiviral GC376, a potential SARS-CoV-2 inhibitor, on model lipid membranes was studied using dynamic light scattering (DLS), UV–VIS spectrometry, Excimer fluorescence, Differential scanning calorimetry (DSC) and Small- and Wide-angle X-ray scattering (SAXS/WAXS). Partitio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Klacsová, Mária, Čelková, Adriána, Búcsi, Alexander, Martínez, Juan Carlos, Uhríková, Daniela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9557139/ http://dx.doi.org/10.1016/j.colsurfb.2022.112918

Ejemplares similares

Crystallization of Feline Coronavirus M(pro) With GC376 Reveals Mechanism of Inhibition
por: Lu, Jimmy, et al.
Publicado: (2022)

Improved SARS-CoV-2 M(pro) inhibitors based on feline antiviral drug GC376: Structural enhancements, increased solubility, and micellar studies
por: Vuong, Wayne, et al.
Publicado: (2021)

N-Terminal Finger Stabilizes the S1 Pocket for the Reversible Feline Drug GC376 in the SARS-CoV-2 M(pro) Dimer
por: Arutyunova, Elena, et al.
Publicado: (2021)

Stabilization of the Dimeric State of SARS-CoV-2 Main Protease by GC376 and Nirmatrelvir
por: Paciaroni, Alessandro, et al.
Publicado: (2023)

Structure basis for inhibition of SARS-CoV-2 by the feline drug GC376
por: Luan, Xiao-dong, et al.
Publicado: (2022)

SARS-CoV-2 3CL(pro) mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376
por: Heilmann, Emmanuel, et al.
Publicado: (2022)

Author Correction: Structure basis for inhibition of SARS-CoV-2 by the feline drug GC376
por: Luan, Xiao-dong, et al.
Publicado: (2022)

The preclinical inhibitor GS441524 in combination with GC376 efficaciously inhibited the proliferation of SARS-CoV-2 in the mouse respiratory tract
por: Shi, Yuejun, et al.
Publicado: (2021)

Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease
por: Fu, Lifeng, et al.
Publicado: (2020)

The Combination of Molnupiravir with Nirmatrelvir or GC376 Has a Synergic Role in the Inhibition of SARS-CoV-2 Replication In Vitro
por: Gidari, Anna, et al.
Publicado: (2022)

Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease
por: Ma, Chunlong, et al.
Publicado: (2020)

Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease
por: Ma, Chunlong, et al.
Publicado: (2020)

Rational Design of Hybrid SARS-CoV-2 Main Protease Inhibitors Guided by the Superimposed Cocrystal Structures with the Peptidomimetic Inhibitors GC-376, Telaprevir, and Boceprevir
por: Xia, Zilei, et al.
Publicado: (2021)

Protease inhibitor GC376 for COVID-19: Lessons learned from feline infectious peritonitis
por: Sharun, Khan, et al.
Publicado: (2020)

Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model
por: Cáceres, C. Joaquín, et al.
Publicado: (2021)

A cysteine protease inhibitor GC376 displays potent antiviral activity against coxsackievirus infection
por: Chen, Yongkang, et al.
Publicado: (2023)

Structural Basis for Inhibiting Porcine Epidemic Diarrhea Virus Replication with the 3C-Like Protease Inhibitor GC376
por: Ye, Gang, et al.
Publicado: (2020)

Cations Do Not Alter the Membrane Structure of POPC—A Lipid With an Intermediate Area
por: Kurakin, Sergei, et al.
Publicado: (2022)

Boceprevir, calpain inhibitors II and XII, and GC-376 have broad-spectrum antiviral activity against coronaviruses in cell culture
por: Hu, Yanmei, et al.
Publicado: (2020)

Discovery of PL(pro) and M(pro) Inhibitors for SARS-CoV-2
por: Puhl, Ana C., et al.
Publicado: (2023)

GC-MS profiling of Bauhinia variegata major phytoconstituents with computational identification of potential lead inhibitors of SARS-CoV-2 M(pro)
por: More-Adate, Pallavi, et al.
Publicado: (2022)

Effect of GS-441524 in combination with the 3C-like protease inhibitor GC376 on the treatment of naturally transmitted feline infectious peritonitis
por: Lv, Jinbao, et al.
Publicado: (2022)

MINOS: Bt 376 - 599 ext - 376 ext - AP (100)
Publicado: (1991)

Differing pan-coronavirus antiviral potency of boceprevir and GC376 in vitro despite discordant molecular docking predictions
por: Wang, Yining, et al.
Publicado: (2022)

Luminescent Assay for the Screening of SARS‐CoV‐2 M(Pro) Inhibitors
por: Sondag, Daan, et al.
Publicado: (2022)

Travaux au bâtiment 376
Publicado: (1992)

Memorandum: attitude of the UA2 collaboration towards document M376
por: CERN. Geneva. SPS Experiments Committee
Publicado: (1984)

Identification of proteasome and caspase inhibitors targeting SARS-CoV-2 M(pro)
por: Wang, Zhengyuan, et al.
Publicado: (2021)

M(pro)-targeted anti-SARS-CoV-2 inhibitor-based drugs
por: She, Zhuxin, et al.
Publicado: (2023)

Facade repair works on building 376
Publicado: (2003)

Aggregation of M3 (E376D) variant of alpha1- antitrypsin
por: Bashir, Arif, et al.
Publicado: (2020)

376. Sensitivity and Specificity of the WHO Probable SARS-CoV-2 Case Definition Among Symptomatic Healthcare Personnel
por: Nguyen, Han, et al.
Publicado: (2021)

Computational repurposing of asthma drugs as potential inhibitors of SARS-CoV-2 M(pro)
por: Hussain, A., et al.
Publicado: (2022)

Review on development of potential inhibitors of SARS-CoV-2 main protease (M(Pro))
por: Katre, Soumya Gulab, et al.
Publicado: (2022)

Discovery of a Novel Trifluoromethyl Diazirine Inhibitor of SARS-CoV-2 M(pro)
por: Citarella, Andrea, et al.
Publicado: (2023)

Autochthonous Peruvian Natural Plants as Potential SARS-CoV-2 M(pro) Main Protease Inhibitors
por: Peralta-Moreno, Maria Nuria, et al.
Publicado: (2023)

Development of 2-chloroquinoline based heterocyclic frameworks as dual inhibitors of SARS-CoV-2 M(Pro) and PL(Pro)
por: Kattula, Bhavita, et al.
Publicado: (2023)

MED12/376: Microbiology and the Hospital Intranet
por: Perera, B
Publicado: (1999)

Microbial Natural Products as Potential Inhibitors of SARS-CoV-2 Main Protease (M(pro))
por: Sayed, Ahmed M., et al.
Publicado: (2020)

Newly synthesized M(pro) inhibitors as potential oral anti-SARS-CoV-2 agents
por: Li, Lin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4qa3pt7e00pffvsj6u3csq35ss